VYNE Therapeutics Inc.VYNENASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank8
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P8
Near historical low
vs 5Y Ago
-2.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -43.38% |
| Q3 2025 | 7.68% |
| Q2 2025 | -20.30% |
| Q1 2025 | -36.76% |
| Q4 2024 | -5.50% |
| Q3 2024 | 40.27% |
| Q2 2024 | 97.03% |
| Q1 2024 | 22.66% |
| Q4 2023 | -8.89% |
| Q3 2023 | -54.13% |
| Q2 2023 | 164.56% |
| Q1 2023 | -36.11% |
| Q4 2022 | -22.85% |
| Q3 2022 | 35.00% |
| Q2 2022 | -7.73% |
| Q1 2022 | -14.96% |
| Q4 2021 | -11.53% |
| Q3 2021 | 17.21% |
| Q2 2021 | 18.64% |
| Q1 2021 | -45.71% |
| Q4 2020 | 18.35% |
| Q3 2020 | -49.52% |
| Q2 2020 | -17.76% |
| Q1 2020 | 35.68% |
| Q4 2019 | -6.85% |
| Q3 2019 | -6.20% |
| Q2 2019 | -15.49% |
| Q1 2019 | 5.62% |
| Q4 2018 | 41.33% |
| Q3 2018 | -34.26% |
| Q2 2018 | 47.24% |
| Q1 2018 | 4.49% |
| Q4 2017 | 31.69% |
| Q3 2017 | 46.67% |
| Q2 2017 | 9.38% |
| Q1 2017 | 22.44% |
| Q4 2016 | 42.95% |
| Q3 2016 | 0.00% |